COLORADO SPRINGS, Colo.,
April 4, 2014 /PRNewswire/ --
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in
cannabis formulation-based drug development and related consulting
is proud to announce plans to enter the State of Nevada where new law expands medical
cannabis opportunities to research, grows, and dispensaries.
As the Company has created a partnership in Michigan to advance state cannabis law and
pursue state-wide initiatives in Michigan, Cannabis Science intends to bring
its know how and resources to Nevada, the state of Cannabis Science's
Incorporation.
The new law marks another milestone in the progression in the
legalization process of the medical cannabis industry in
the United States -- one that is
aimed at ways of managing multiple ailments for patients. In
addition, the new law is expected to contribute to the creation of
new sources of revenue and employment opportunities within the
state. Cannabis Science is well positioned to bring novel
patient-based initiatives to Nevada.
"Nevada is another key state in
which we, as Nevada incorporate
company, can deliver cannabis-based products and medical care to
patients. As Nevada legislation continues to develop, our
Michigan state-based experience
puts Cannabis Science in an advantageous position to develop new
opportunities in Nevada," stated
Dr. Dorothy Bray, Director and CEO
of Cannabis Science, Inc.
Nevada originally introduced
their medical cannabis program on a patient level in 2001.
The new law, effective as of April 1,
2014, allows for the buying, selling, and testing of
cannabis as regulated, and the taxation of cannabis revenues.
Licenses for these types of businesses will be issued, and patients
can expect doors to open around January 1,
2015.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824
SOURCE Cannabis Science, Inc.